查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1627676

人類胰島素市場：未來預測（2025-2030）

Human Insulin Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

人類胰島素市場預計將以 3.28% 的複合年成長率成長，到 2025 年市場規模將達到 233.3445 億美元，到 2030 年將達到 274.2171 億美元。

胰島素是一種控制體內糖水平的荷爾蒙。糖尿病是一種慢性代謝疾病，涉及血糖值或糖水平異常升高。目前，糖尿病有兩種類型：在第 1 型糖尿病中，胰臟中的 BETA 細胞停止分泌胰島素；而在第 2 型糖尿病中，身體細胞對胰島素分泌的敏感度降低。隨著久坐生活方式的增加，胰島素市場的糖尿病盛行率預計將飆升。此外，新興國家良好的報銷趨勢也有望促進整體市場的成長。

人類胰島素市場促進因素

  • 糖尿病患者數量的增加將促進人類胰島素市場的成長

糖尿病是一種慢性代謝疾病，其特徵是低血糖導致血糖值升高。糖尿病是一種慢性代謝疾病，其中血糖濃度升高會導致低血糖。人類擁有人類胰島素，廣泛用於個人化治療、臨床照護中的胰島素替代以及治療和控制疾病的專科療法。然而，治療第 1 型糖尿病的藥物消耗量不斷增加進一步推動了對胰島素的需求，這些藥物透過提供人體無法形成的必需胰島素來控制血糖值並預防高血糖。它是口服的，旨在改善葡萄糖的吸收並增加體內的胰島素量。

此外，由於對胰島素幫浦治療產品的需求不斷增加，市場也不斷擴大，這種產品模仿健康胰臟的基礎胰島素分泌，並全天持續供應胰島素。此外，人體胰島素對於預防術前和重症加護環境中的高血糖和低血糖變化也至關重要，因此對於減少手術併發症至關重要。

人類胰島素市場的地理展望：

  • 預測期內，北美將呈現指數級成長。

由於久坐的生活方式導致北美糖尿病盛行率高，美國在全球人類胰島素市場佔據主導地位。在美國，成本因素是主要問題，因為國內胰島素製造商賺取了大約一半的收益。美國佔了長效胰島素藥物 Lantus 全球銷售額的大部分。許多醣尿病藥物製造商都將中國視為擴大全球銷售的關鍵市場。 Lantus 是世界上最受歡迎的基礎胰島素，佔據美國市場的主導地位。

為什麼要購買這份報告？

  • 深刻的分析：獲得深入的市場洞察，涵蓋主要地區和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場促進因素和未來趨勢：探索動態因素和關鍵市場趨勢以及它們將如何影響市場的未來發展。
  • 可行的建議：利用洞察力進行策略決策，在動態環境中開闢新的業務流和收益。
  • 適合廣泛的用戶：對於新興企業、研究機構、顧問公司、中小企業和大型企業來說，它都是實用且具有成本效益的。

它有什麼用途？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

分析範圍

  • 歷史資料與預測（2022-2030）
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭對手定位、策略與市場佔有率分析
  • 按部門和地區（國家）分類的收益成長和預測分析
  • 公司簡介（策略、產品、財務資訊、主要趨勢等）

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 分析範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第 2 章 分析方法

  • 分析設計
  • 分析過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第 5 章 人類胰島素市場（依產品類型）

  • 介紹
  • 速效胰島素
  • 長效胰島素
  • 結合胰島素
  • 生物相似藥
  • 其他

6. 人類胰島素市場依應用分類

  • 介紹
  • 1 型糖尿病
  • 2 型糖尿病

7. 人類胰島素市場（按分銷管道）

  • 介紹
  • 醫院
  • 零售藥局
  • 其他

8. 人類胰島素市場（按地區）

  • 介紹
  • 北美洲
    • 依產品類型
    • 按應用
    • 按分銷管道
    • 按國家
  • 南美洲
    • 依產品類型
    • 按應用
    • 按分銷管道
    • 按國家
  • 歐洲
    • 依產品類型
    • 按應用
    • 按分銷管道
    • 按國家
  • 中東和非洲
    • 依產品類型
    • 按應用
    • 按分銷管道
    • 按國家
  • 亞太地區
    • 依產品類型
    • 按應用
    • 按分銷管道
    • 按國家

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 企業合併（M&A）、協議、商業合作
  • 競爭儀錶板

第10章 公司簡介

  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • Biocon
  • Boehringer Ingelheim
  • Tonghua Dongbao Pharmaceutical Co.
  • Wockhardt
  • Julphar
  • Gan & Lee Pharmaceuticals
  • Biocon
  • Bioton
  • Novo Nordisk Pharmatech
  • Sigma-Aldrich
  • CDH Fine Chemical
  • BioGems
簡介目錄
Product Code: KSI061615637

The human insulin market is expected to grow at a CAGR of 3.28%, reaching a market size of US$27,421.71 million in 2030 from US$23,334.45 million in 2025.

Insulin is the hormone that controls sugar levels in the body. Diabetes is a chronic metabolic condition with an abnormal increase in blood glucose or sugar levels. Currently, it has two types. In type 1 diabetes, the pancreatic beta cells are unable to secrete insulin, whereas in type 2, the cells of the body become less sensitive to insulin secretion. With the increasing prevalence of sedentary lifestyles, the incidence of diabetes is anticipated to surge in the insulin market. In addition, favorable reimbursement trends in developed countries are expected to contribute to overall market growth.

Human Insulin Market Drivers

  • Rising cases of diabetes are contributing to the human insulin market growth

Diabetes is a chronic metabolic ailment that has been defined through increased blood glucose levels in the blood hypoglycemia. Humans have human insulin, which is widely used in individualized treatment, insulin replacement in clinical therapy, and specialty treatment to treat and control the disease. However, the demand for insulin is further propelled by the increasing consumption of the drug to treat type 1 diabetes, which controls blood sugar levels and prevents hyperglycemia by providing the essential insulin that does not form in the body. It is used orally and is designed to improve glucose uptake and increase the amount of insulin in the body.

Further, the market is also expanding due to the increasing demand for insulin pump therapy products that provide a continuous flow of insulin all day, mimicking the basal insulin secretion by a healthy pancreas. In addition to that, human insulin is also very important in preventing high or low-glucose shifts in preoperative and critical care environments and, hence, is imperative in lessening surgical complications.

Human Insulin Market Geographical Outlook:

  • North America is witnessing exponential growth during the forecast period.

The high prevalence of diabetes in North America, which is caused by a sedentary lifestyle, has resulted in the United States gaining a stranglehold on the global human insulin market. The cost factor is the biggest concern in the US since domestic insulin producers receive about half of their revenue. The United States accounts for most of the global sales of Lantus, a long-acting insulin. Many diabetes medication manufacturers view the country as a key market to boost global sales. Lantus is the most popular basal insulin worldwide and holds a monopoly on the US market.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The human insulin market is segmented and analyzed as follows:

By Product Type

  • Rapid-Acting Insulin
  • Long-Acting Insulin
  • Combination Insulin
  • Biosimilar
  • Others

By Application

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus

By Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HUMAN INSULIN MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Rapid-Acting Insulin
  • 5.3. Long-Acting Insulin
  • 5.4. Combination Insulin
  • 5.5. Biosimilar
  • 5.6. Others

6. HUMAN INSULIN MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Type 1 Diabetes Mellitus
  • 6.3. Type 2 Diabetes Mellitus

7. HUMAN INSULIN MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Retail Pharmacies
  • 7.4. Others

8. HUMAN INSULIN MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Application
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Application
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Italy
      • 8.4.4.5. Spain
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Application
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Application
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Eli Lilly and Company
  • 10.2. Sanofi
  • 10.3. Novo Nordisk A/S
  • 10.4. Biocon
  • 10.5. Boehringer Ingelheim
  • 10.6. Tonghua Dongbao Pharmaceutical Co.
  • 10.7. Wockhardt
  • 10.8. Julphar
  • 10.9. Gan & Lee Pharmaceuticals
  • 10.10. Biocon
  • 10.11. Bioton
  • 10.12. Novo Nordisk Pharmatech
  • 10.13. Sigma-Aldrich
  • 10.14. CDH Fine Chemical
  • 10.15. BioGems